BioStem Technologies, Inc.
BSEM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.00 | -0.01 | 0.16 |
| FCF Yield | 10.62% | -4.49% | -6.18% | -1.25% |
| EV / EBITDA | 6.61 | -11.23 | -5.91 | -27.65 |
| Quality | ||||
| ROIC | 71.34% | -226.80% | -371.76% | 190.54% |
| Gross Margin | 95.37% | 92.44% | 87.17% | 66.03% |
| Cash Conversion Ratio | 0.77 | 0.41 | 0.23 | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 252.77% | 56.65% | 39.70% | 18.17% |
| Free Cash Flow Growth | 767.26% | -71.11% | -1,283.20% | 73.98% |
| Safety | ||||
| Net Debt / EBITDA | -0.58 | -0.60 | -0.68 | -7.46 |
| Interest Coverage | 53.13 | -11.11 | -10.00 | -3.05 |
| Efficiency | ||||
| Inventory Turnover | 7.54 | 1.92 | 2.23 | 5.67 |
| Cash Conversion Cycle | 36.44 | 36.71 | 145.44 | -70.60 |